Whole Blood Pathogen Reduction (WBPR) Investigator Initiated Award — Defense Health Agency Contracting Activity - DHACA funding opportunity
Defense Health Agency Contracting Activity - DHACA · Federal agency

Whole Blood Pathogen Reduction (WBPR) Investigator Initiated Award

Applications for the Combat Casualty Care Research Program are being solicited by the Assistant Secretary of Defense for Health Affairs, Defense Health Program (DHP). The Combat Casualty Care Research Program (CCCRP) pro...

80
match
Award $0–$3.5M Deadline 5280 days ago Location Alabama Type grant Level Federal Closed posted Oct 4, 2011
✦ AI Summary
  • Who can apply: Federal-level applicants (see eligibility for details).
  • Funding amount: up to $3,500,000 (total pool ~$3,500,000).
  • Next deadline: January 5, 2012.
  • Issued by: Defense Health Agency Contracting Activity - DHACA.
How was this generated?

The “key facts” mode pulls structured fields directly from the official source posting (amount, deadline, eligibility tags). The AI mode adds a short plain-English narrative on top, generated from the same source. Always verify with the agency before applying.

AI-generated. Always verify with the official source.

Award amount
$0–$3.5M
Deadline
5280 days ago
Jan 5, 2012
Total pool
$3.5M

About this opportunity

Applications for the Combat Casualty Care Research Program are being solicited by the Assistant Secretary of Defense for Health Affairs, Defense Health Program (DHP). The Combat Casualty Care Research Program (CCCRP) provides resources for advances in biotechnology research administered by the Telemedicine and Advanced Technology Research Center (TATRC), located at Fort Detrick, Maryland. TATRC is administering the application process for this Program Announcement/Funding Opportunity, and the Army Medical Research Acquisition Activity (USAMRAA) is issuing this Program Announcement and will be negotiating all resulting awards. With this Program Announcement/Funding Opportunity, the Army Medical Research and Materiel Command (USAMRMC) is seeking to fund biotechnology research that culminates in outcomes and technologies that benefit civilian and military applications. With this Program Announcement/Funding Opportunity, the Army Medical Research and Materiel Command (USAMRMC) is seeking to fund biotechnology research that culminates in outcomes and products that may qualify as advanced development activities within the Department of Defense (DoD). The results of this research will support medical protection and treatment requirements and needs by leveraging the skills and talents of based businesses and teaching-research academic institutions. The intent is to create enduring initiatives and collaborations that will develop and support sustained business and enterprise solutions. The results of the research funded through this Program Announcement/Funding Opportunity are expected to increase the body of knowledge available to professionals and practitioners in health, medical science and related fields. The research impact is expected to benefit both civilian and military communities, particularly as it relates to the priority topic area described below. This topic area contributes in a step-wise manner to the long-term goal of the Department of Defense to develop a FDA (Food and Drug Administration) licensable pathogen reduction device/ methodology wherein whole blood may be treated and then further processed as needed to produce pathogen-reduced red whole blood for transfusion. Specifically, the present program is for the development of methodology for whole blood and the production of FDA licensable red cells. By the end of the award period, the product should have completed FDA phase I and II clinical trials, or equivalent, in accordance with FDA requirements. The requirements identified in this topic area are to develop a process of pathogen reduction for treating emergency fresh whole blood with a safe, non-toxic (in humans) methodology, (a) to inactivate parasites ( .Babesia, Malaria, T. Cruzi),(b) to inactivate donor white blood cells,(c) to inactivate/reduce the amount of virus load ( HCV, HBC, HIV), (d) to inactivate clinically significant bacteria, (e) to demonstrate viability and suitability of derived red cells and (f) to demonstrate potential for further development for production of whole blood.

Funding agency

Tags

Want help applying?

Our specialists will check your eligibility, prepare the application, and walk you through every step — for free. Create a free account →

Who can apply

Eligibility details aren't on file yet — check the agency source link in the Documents tab for the latest rules.

Geographic eligibility

  • Alabama
  • Alaska
  • Arizona
  • Arkansas
  • California
  • Colorado
  • Connecticut
  • Delaware
  • Florida
  • Georgia
  • Hawaii
  • Idaho
  • Illinois
  • Indiana
  • Iowa
  • Kansas
  • Kentucky
  • Louisiana
  • Maine
  • Maryland
  • Massachusetts
  • Michigan
  • Minnesota
  • Mississippi
  • Missouri
  • Montana
  • Nebraska
  • Nevada
  • New Hampshire
  • New Jersey
  • New Mexico
  • New York
  • North Carolina
  • North Dakota
  • Ohio
  • Oklahoma
  • Oregon
  • Pennsylvania
  • Rhode Island
  • South Carolina
  • South Dakota
  • Tennessee
  • Texas
  • Utah
  • Vermont
  • Virginia
  • Washington
  • West Virginia
  • Wisconsin
  • Wyoming
  • District of Columbia

How to apply

We don't have application instructions on file yet — head straight to the official source.

Apply on agency site
Tip from our team:

Read the agency's eligibility checklist before you start — it's almost always shorter than the full NOFO and will tell you in 90 seconds whether to keep going.

Need help getting in touch with the right agency contact?

Create a free account and our specialists will guide you through the application end-to-end.

Source documents

View on agency site
Canonical NOFO, application packet, and forms
No supplemental documents yet.

Direct downloads (NOFO PDFs, application forms, FAQs) will appear here once our team attaches them. For now, the agency site has the canonical packet.

Citation details

Source systemgrants.gov
Source ID126473
PostedOct 4, 2011

Frequently asked questions

No FAQs yet.

Have a question about this fund? Sign in to open a ticket about this fund.